Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates
Dr. London is a global leader in veterinary targeted therapies. She discusses potential risks to veterinary staff, the value of targeted therapy in times of constrained PPE resources, and the effects of COVID-19 on research activity.
Nucleic acids are the “building blocks” of life; they determine all inherited characteristics in life and direct the process of protein synthesis. These important biomolecules create, encode and store information in all cells.
Next-generation sequencing (NGS) technology gives veterinarians the ability to generate a tremendous amount of comprehensive data and this information allows for a much deeper understanding of cancer pathogenesis and behavior.
This is a big and stressful moment for the country. We want to take a moment to acknowledge that for all of us.
At FidoCure®, we were fortunate to make progress on our mission to advance canine cancer treatment, despite the challenges of 2020.
Not only are we working hard to expand our canine cancer toolbox, we’re continually working to improve the user experience for veterinarians.
When your dog has cancer and you're also a world-renowned cancer researcher, your interactions with veterinary oncologists are a little different.
Another exciting addition to the FidoCure® oncology toolbox: Olaparib as a new targeted therapy.
Safety and Toxicity of Small Molecule Inhibitors in Dogs with Spontaneously Occurring Malignancies — The Use of Real World Data
The VCS Virtual Conference was held from October 15 - 17, 2020. We had the honor of presenting our abstract during the event.
Dr. Ehrhart shares insight from her current work in comparative aging research and highlights its intersection with cancer and musculoskeletal research in veterinary medicine.Webinars